Chronic heart failure is a clinical syndrome of cardiac insufficiency caused by various heart diseases. It is the terminal stage of various cardiovascular diseases such as coronary heart disease, rheumatic heart disease, and high heart disease. It is regarded as the end of life of cardiovascular diseases. Front station, the final battlefield of human heart disease. However, the recommended treatment drugs for chronic heart failure in the relevant guidelines issued by European and American countries, the evidence-based medicine evidence was completed around the 1990s. Drugs with evidence-based medical research evidence have rarely progressed, and there have been no significant breakthroughs.
Under the guidance of TCM context theory, Yiling Pharma discussed the pathogenesis and treatment of chronic heart failure in TCM, and concluded that “Deficiency of qi and yang is the root of the disease, stasis of sun collaterals is the key link, and accumulation of collaterals is an aggravating factor”. Based on this, the treatment strategy of “invigorating the temperature of the yang, promoting blood circulation and dredging collaterals, and diuresis to reduce swelling” was established. Formulated the formula of Qili Qiangxin Capsule.
The completed evidence-based medicine research results of Qili Qiangxin Capsule in the treatment of 512 cases of chronic heart failure confirmed that the addition of Qili Qiangxin Capsule on the basis of international standard treatment can effectively reduce the amino acid that marks the severity of heart failure. The level of terminal B-type natriuretic peptide precursor increases the 6-min walking distance in patients with heart failure, improves the Minnesota quality of life score, significantly improves the clinical efficacy by 16%, improves cardiac function, and reduces the incidence of composite endpoint events. The results of the study were published in the Journal of the American College of Cardiology (JACC), and the editorial department issued a review “Making the Failing Heart Stronger—Inspiration from Traditional Chinese Medicine”, which pointed out: “Now this rich Promising research shows that using the latest technology to study active ingredients in traditional Chinese medicine opens the door to hope for synergistic effects in the treatment of heart failure.”
This evidence-based study was included in the JACC 2013 Academic Highlights and included in Nature reviews cardiology, a sub-journal of Nature, which shows that Tongluo Compound Qili Qiangxin Capsule is widely recognized and highly regarded by the international medical community. affim. Professor Anthony, associate editor of The New England Journal of Medicine, commented: “The clinical study of Qiliqiangxin is very exciting. This is a double-blind, placebo-controlled, high-quality trial with very encouraging results.” Circulation Research commented: “The evidence-based study of Qili Qiangxin Capsules has attracted great attention in the medical field in the United States”. The Heart.org in the United Kingdom, “Medical News Today” and other media reported this study by experts as a milestone in the treatment of chronic heart failure with traditional Chinese medicine in recent years.
Basic research shows that Qili Qiangxin Capsule can not only strengthen the heart and diuresis, dilate blood vessels to treat the symptoms, but also inhibit the excessive activation of the neuroendocrine system, reduce the remodeling of the ventricle to treat the root cause, and play the role of “treat both the symptoms and the root causes” of chronic heart failure. The action characteristics and therapeutic advantages of multiple links, multiple pathways, and multiple targets also reveal the therapeutic mechanism of Qili Qiangxin Capsules in the prevention and treatment of chronic heart failure.
The research on the treatment of chronic heart failure with Qili Qiangxin Capsule won the first prize of the National Science and Technology Progress Award in 2019, and the relevant research results were included in the 11th edition of the textbook “Integrated Chinese and Western Medicine”. Evidence and good clinical efficacy, Qili Qiangxin Capsule is listed in the “China Heart Failure Diagnosis and Treatment Guidelines” (2014, 2018), “Heart Failure” issued by the Chinese Medical Association, China Association of Integrative Medicine, China Heart Failure Alliance Expert consensus on the diagnosis and treatment of failure with integrated traditional Chinese and western medicine (2016), “Expert Suggestions on Early Prevention and Treatment of Diastolic Heart Failure” (2021) and “Guidelines for Clinical Application of Chinese Patent Medicines in the Treatment of Heart Failure (2021)”, which are also among the few included Chinese patent medicine recommended by the “Guidelines for Diagnosis and Treatment of Dilated Cardiomyopathy in China” (2018) issued by the Chinese Medical Association.